Literature DB >> 3029267

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo.

M K Jenkins, R H Schwartz.   

Abstract

We investigated the antigen specificity and presentation requirements for inactivation of T lymphocytes in vitro and in vivo. In vitro studies revealed that splenocytes treated with the crosslinker 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (ECDI) and soluble antigen fragments failed to stimulate significant proliferation by normal pigeon cytochrome c-specific T cell clones, suggesting that the chemical treatment inactivated full antigen presentation function. However, T cell clones exposed to ECDI-treated splenocytes and antigen in vitro were rendered unresponsive for at least 8 d to subsequent antigen stimulation with normal presenting cells. As predicted by the in vitro results, specific T cell unresponsiveness was also induced in vivo in B10.A mice injected intravenously with B10.A, but not B10.A(4R), splenocytes coupled with pigeon cytochrome c via ECDI. The antigen and MHC specificity of the induction of this T cell unresponsiveness in vitro and in vivo was identical to that required for T cell activation. These results suggest that nonmitogenic T cell recognition of antigen/MHC on ECDI-modified APCs results in the functional inactivation of T cell clones.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3029267      PMCID: PMC2188516          DOI: 10.1084/jem.165.2.302

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  48 in total

Review 1.  T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex.

Authors:  R H Schwartz
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

2.  The T lymphocyte response to cytochrome c. V. Determination of the minimal peptide size required for stimulation of T cell clones and assessment of the contribution of each residue beyond this size to antigenic potency.

Authors:  R H Schwartz; B S Fox; E Fraga; C Chen; B Singh
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

Review 3.  The complexity of structures involved in T-cell activation.

Authors:  J W Goodman; E E Sercarz
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

4.  Evidence from in vitro studies that tolerance to self antigens is MHC-restricted.

Authors:  H G Rammensee; M J Bevan
Journal:  Nature       Date:  1984 Apr 19-25       Impact factor: 49.962

5.  Monoclonal antibodies against rat immunoglobulin kappa chains.

Authors:  L L Lanier; G A Gutman; D E Lewis; S T Griswold; N L Warner
Journal:  Hybridoma       Date:  1982

Review 6.  Cellular mechanisms of immunologic tolerance.

Authors:  G J Nossal
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

Review 7.  Studies of immune responsiveness and unresponsiveness to the p-azobenzenearsonate (ABA) hapten.

Authors:  J G Monroe; A Lowy; R D Granstein; M I Greene
Journal:  Immunol Rev       Date:  1984-08       Impact factor: 12.988

8.  Immunoregulatory pathways in adult responder mice. II. Regulation of delayed-type hypersensitivity responses by GAT-specific suppressor factors present in GAT-tolerant adult responder mice.

Authors:  M K Jenkins; C Waltenbaugh; S D Miller
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  Antigen presentation by resting B cells. Radiosensitivity of the antigen-presentation function and two distinct pathways of T cell activation.

Authors:  J D Ashwell; A L DeFranco; W E Paul; R H Schwartz
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

10.  T cell tolerance studied at the level of antigenic determinants. I. Latent reactivity to lysozyme peptides that lack suppressogenic epitopes can be revealed in lysozyme-tolerant mice.

Authors:  A Oki; E Sercarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  287 in total

Review 1.  Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?

Authors:  K Honey; S P Cobbold; H Waldmann
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Membrane domains and the immunological synapse: keeping T cells resting and ready.

Authors:  Michael L Dustin
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

3.  Induction of T cell anergy by liposomes with incorporated major histocompatibility complex (MHC) II/peptide complexes.

Authors:  A J van Rensen; L S Taams; M C Grosfeld-Stulemeyer; W van Eden; D J Crommelin; M H Wauben
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 4.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

5.  Liposomes with incorporated MHC class II/peptide complexes as antigen presenting vesicles for specific T cell activation.

Authors:  A J van Rensen; M H Wauben; M C Grosfeld-Stulemeyer; W van Eden; D J Crommelin
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 6.  The immunological synapse.

Authors:  Michael L Dustin
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

7.  The tumour associated cell surface antigen A6H is costimulatory for human CD4+ but not CD8+ T cells.

Authors:  T Labuda; E Parra; G Hedlund; T Kalland; M Dohlsten
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

8.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  "Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.

Authors:  T F Gajewski; D W Lancki; R Stack; F W Fitch
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

10.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.